<DOC>
	<DOCNO>NCT02308280</DOCNO>
	<brief_summary>Multiple myeloma morbid disease associate poor outcome , particularly high-risk cytogenetics . While standard therapy modestly improve survival high-risk patient , myeloma remain incurable . To date , potential curative treatment remain allogeneic hematopoietic stem cell transplantation . However , high incidence toxicity include chronic GVHD disease progression currently two important obstacle therapy . Better approach maintain improve benefit allogeneic transplant , decrease toxicity , urgently need . The investigator hypothesize Bortezomib administration non myeloablative allogeneic hematopoietic stem cell transplantation high-risk myeloma patient might improve outcome patient decrease myeloma relapse severity chronic GVHD preserve graft-versus-myeloma effect . Our goal improve poor clinical outcome high-risk myeloma patient .</brief_summary>
	<brief_title>Nonmyeloablative Allogeneic Stem Cell Transplant Followed Bortezomib High-risk Multiple Myeloma Patients</brief_title>
	<detailed_description>To date , potential curative treatment multiple myeloma remain allogeneic hematopoietic stem cell transplantation . Achievement remission myeloma patient allotransplanted advanced disease , achievement complete response relapse patient follow infusion donor leucocyte infusion , decrease incidence relapse associate chronic GVHD , good survival myeloma patient relapse allogeneic transplant rescue medication production allo-immune response allogeneic transplant , support existence graft-versus-myeloma effect . However , chronic GVHD participate morbidity mortality allogeneic transplantation , addition significant relapse rate despite transplantation two important obstacle therapeutic modality myeloma . Bortezomib ( VelcadeTM ) dipeptidyl boronic acid-based reversible proteasome inhibitor . Several mechanisms action propose effect multiple myeloma : direct induction myeloma cell apoptosis , inhibition NF-κB activation , reduction myeloma cell adherence bone marrow microenvironment ( decrease drug resistance ) , inhibition production , secretion intracellular signal myeloma-mediators . It one effective drug treatment multiple myeloma . As consolidation treatment autologous stem cell transplantation , drug associate improvement response rate importantly , quality depth response . Maintenance treatment Bortezomib autologous transplantation lead survival improvement , benefit particularly obvious myeloma patient high-risk cytogenetics carry del ( 17p13 ) . In addition anti-myeloma property , Bortezomib immunomodulatory effect . Indeed , proteasome inhibitor affect several aspect immune inflammatory response interfere antigen present cell function effector cell function . Given immunomodulatory property , Bortezomib recently show safe effective HLA-mismatched reduced-intensity conditioning transplantation GVHD prophylaxis . This prospective phase II , open label , single institution study evaluate novel treatment strategy newly diagnose multiple myeloma patient high-risk disease patient ≤ 50 year old . After optimal Bortezomib-based induction treatment ( VTD , CyBorD , RVD PAD [ patient plasma cell leukemia ] ) minimum 4 cycle , follow Melphalan ≥ 140 mg/m2 autologous stem cell transplantation , eligible patient accept participate include study . Within 6 month autologous transplantation , patient receive non myeloablative allogeneic transplantation . Patients 6/6 compatible sibling donor receive conditioning regimen Fludarabine 30 mg/m2 Cyclophosphamide 300 mg/m2 per day 5 day day -8 day -4 3 rest day donor stem cell infusion day 0 . Patients without sibling donor 8/8 allele match unrelated donor receive condition regimen Fludarabine 30 mg/m2 per day 3 day day -4 -2 TBI 2 Gy day -1 donor stem cell infusion day 0 . In sibling transplant recipient , GVHD prophylaxis consist Tacrolimus 3 mg p.o . BID start day -8 , adjust thrice weekly obtain blood level 8-12 ng/mL . Tacrolimus taper start day +50 complete day +100 absence GVHD . In matched unrelated donor recipient , Tacrolimus initiate sibling , start day -4 , taper initiate day +100 complete day +180 absence GVHD . MMF 15 mg/kg p.o . BID give day +1 +50 sibling recipient . It give dose TID day +1 +40 , taper gradually day +100 match unrelated donor recipient . Patients without progressive disease allogeneic transplantation receive Bortezomib 1.3 mg/m2 s.c. every 14 day ± 3 day start day +120 , total 26 dos ( 1 year treatment ) . Patients follow regularly disease evaluation , use IMWG criterion . Toxicity evaluate use NCI common terminology criterion adverse event ( CTCAE ) version 4.0 . Occurrence severity acute GVHD evaluate use modify Glucksberg criterion . Chronic GVHD evaluate use NIH criterion . The trial terminate patient follow 5 year allogeneic hematopoietic stem cell transplantation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Age 18 65 year , inclusively Newly diagnose multiple myeloma patient ( accord IMWG criterion ) measurable disease diagnosis , base presence follow : 1 . Serum intact immunoglobulin ≥ 10 g/L ; 2 . BenceJones proteinuria ≥ 200 mg/day ; 3 . Serum free light chain ( sFLC ) assay ≥ 100 mg/L ( difference involve uninvolved FLC level ) abnormal sFLC ratio Highrisk patient present follow : 1. International Staging System ( ISS ) III ; 2. del ( 17p13 ) , ( 4 ; 14 ) ISS II III , ( 14 ; 16 ) , ( 14 ; 20 ) chromosome 1 abnormality FISH . At time , international consensus threshold consider cytogenetic abnormality significant . For study , investigator consider arbitrarily percentage ≥ 10 % significant . 3 . Plasma cell leukemia , define absolute blood plasma cell count &gt; 2 x 109/L presence &gt; 20 % plasma cell among peripheral blood white cell ; 4 . Patients ≤ 50 year , regardless cytogenetics ISS stage Having receive Bortezomibcontaining regimen ( VTD , CyBorD , VRD PAD [ patient PCL ] ) minimum 4 cycle ≥ PR . Received highdose Melphalan ≥ 140 mg/m2 follow autologous stem cell transplantation . Available HLAidentical sibling donor 8/8 allele match ( HLAA , B , C , DR ) match unrelated donor Failure achieve least PR Bortezomibbased induction therapy . Progressive disease time Having receive tandem autologous stem cell transplantation . Having receive maintenance consolidation therapy Bortezomib ASCT . If delay allogeneic transplant expect , Lenalidomide 10 mg die maximum three month allow ASCT ( initiate day +90 ) discontinue least 14 day start condition regimen . Karnofsky score &lt; 70 % comorbidity index HCTCI &gt; 3 . Bilirubin &gt; 2 x upper limit normal ( ULN ) unless felt related Gilbert 's disease hemolysis ; AST ALT &gt; 2.5 x ULN ; alkaline phosphatase &gt; 5 x ULN . Peripheral neuropathy neuropathic pain ≥ grade II . Poor organ function Known hypersensitivity boron , mannitol Bortezomib . Active infection follow virus : HIV , HTLV1 2 , hepatitis B ( define HBsAg positivity ) hepatitis C ( define antiHCV positivity HCVRNA positivity ) . Presence another malignancy expect survival estimate &lt; 75 % 5 year ( complete resection basal cell carcinoma squamous cell carcinoma skin , complete resection ductal carcinoma situ breast , presence lobular carcinoma situ breast , complete resection carcinoma situ cervix , situ lowrisk prostate cancer curative therapy exclusion criterion ) . Positive βhCG pregnancy test . Female study participant surgically sterile ( hysterectomy ) postmenopausal least 12 consecutive month automatically eligible criterion . Study participant agree remain abstinent practice doublebarrier form birth control trial screen 90 day last dose Bortezomib . Women lactate . Women childbearing potential planning become pregnant enrol study 30 day last Bortezomib injection . Participation trial investigational agent within 30 day prior entry study . Inability provide write informed consent prior initiation studyrelated procedure , inability , opinion investigator , comply requirement study Estimated probability survive le 6 month allogeneic transplant . Suspicion cardiac amyloidosis . Current history drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>High-risk myeloma</keyword>
	<keyword>Non myeloablative allogeneic transplantation</keyword>
	<keyword>Bortezomib</keyword>
</DOC>